US-based Varian Medical Systems has entered an agreement to purchase all outstanding shares of Australian life sciences firm Sirtex Medical for about A$1.58bn ($1.28bn).

The deal is in line with Varian’s strategy for long-term growth and is expected to strengthen the firm’s position in radiation medicine and interventional oncology segments.

Varian plans to combine its expertise in treatment planning and delivery, image guidance and processing, oncology practice management software, and radiation safety with Sirtex’s interventional oncology platform to deliver better care solutions for cancer patients.

Varian Medical Systems CEO Dow Wilson said: “This acquisition is the latest step in Varian’s long-term strategy to become a global leader in multi-disciplinary integrated cancer care solutions.

“The combination of the two companies will expand the reach of the Sirtex platform by making it more broadly available to the clinical community.

“The combination of the two companies will expand the reach of the Sirtex platform by making it more broadly available to the clinical community.”

“Our companies share a common vision of a world without fear of cancer, and we look forward to completing this acquisition and positively impacting more patients’ lives around the world.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sirtex’s lead product SIR-Spheres Y-90 resin microspheres is a targeted internal radiation therapy indicated for certain types of liver cancers in more than 40 countries.

With operations in the US, Europe, and Asia, the firm has reported annual revenues of A$234m ($189.13m) in the fiscal year ending on 30 June 2017.

Set to be completed in late May this year, the transaction is subject to shareholders and regulatory approvals, as well as other customary closing conditions.